← Back to patent-cliff list
瑞舒伐他汀钙/非马沙坦钾三水合物
Tier C — Watch / tradeFimasartan potassium trihydrate/Rosuvastatin calcium
韩国保宁制药株式会社
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：AT1、HMGCR
Brand：Tuvero
Indications (approved)：高血压、血脂障碍
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fimasartan potassium trihydrate/Rosuvastatin calcium?
Approved indications include: 高血压, 血脂障碍.
When does the Fimasartan potassium trihydrate/Rosuvastatin calcium patent expire?
No public expiry year is available for Fimasartan potassium trihydrate/Rosuvastatin calcium yet; this page updates once verified.
How do I get a quote for Fimasartan potassium trihydrate/Rosuvastatin calcium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24